← The Wire
IMMXNasdaq
Immix Biopharma, Inc.
Pharmaceutical Preparations · DE · CIK 1873835
Immix Biopharma applies CAR-T cell therapy to treat AL Amyloidosis and other serious diseases
$602M
Market cap
$10.49
Last close
+5.1%
1D
+11.6%
5D
1.9M
Volume
Price · last 39 sessions+10.7%
May 4L $7.87 · H $10.66Jun 29
82
Total filings
May 29, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteMay 29, 20268-KCompany UpdateMay 21, 2026424B5424B5May 21, 20268-KReg FD Disclosure · Company UpdateMay 21, 202610-Q10-QMay 7, 2026DEFA14ADEFA14AApr 6, 2026DEF 14ADEF 14AApr 6, 20268-KReg FD Disclosure · Company UpdateMar 30, 202610-K/A10-K/AMar 27, 20268-KMaterial AgreementMar 25, 2026424B5424B5Mar 25, 202610-K10-KMar 25, 20268-KMaterial AgreementDec 8, 2025424B5424B5Dec 8, 20258-KReg FD Disclosure · Company UpdateDec 8, 20258-KCompany UpdateNov 26, 202510-Q10-QNov 7, 20258-KExecutive Change · Material AgreementSep 8, 202510-Q10-QAug 8, 20258-KShareholder VoteJun 23, 2025424B5424B5Jun 3, 20258-KMaterial AgreementJun 3, 202510-Q/A10-Q/AMay 19, 2025DEFA14ADEFA14AMay 19, 202510-K/A10-K/AMay 19, 202510-Q10-QMay 8, 2025DEFA14ADEFA14AMay 5, 2025DEF 14ADEF 14AApr 30, 202510-K10-KMar 25, 202510-Q10-QNov 12, 202410-Q10-QAug 12, 20248-KCompany UpdateJul 26, 20248-KAuditor ChangeJul 22, 20248-KExecutive Change · Shareholder VoteJun 14, 2024DEFA14ADEFA14AMay 21, 20248-KEquity Issuance · Company UpdateMay 20, 202410-Q10-QMay 9, 2024DEF 14ADEF 14AApr 29, 202410-K10-KMar 29, 2024424B5424B5Feb 7, 2024SC 13GSC 13GFeb 7, 20248-KMaterial Agreement · Company UpdateFeb 6, 2024424B5424B5Feb 5, 20248-KCompany UpdateFeb 5, 202410-Q10-QNov 13, 2023SC 13DGKCC SCHEDULE 13DAug 30, 20238-KExecutive Change · Material AgreementAug 22, 202310-Q10-QAug 11, 2023424B5424B5Jul 14, 20238-KMaterial AgreementJul 14, 20238-KShareholder VoteJun 8, 202310-Q10-QMay 12, 2023DEFA14ADEFA14AApr 25, 2023DEF 14ADEF 14AApr 25, 202310-K10-KMar 27, 2023424B5424B5Mar 22, 20238-KMaterial AgreementMar 22, 20238-K/AReg FD DisclosureMar 13, 20238-KMaterial AgreementMar 13, 20238-KMaterial Agreement · Equity IssuanceJan 18, 20238-KReg FD DisclosureDec 16, 20228-KMaterial Agreement · Company UpdateDec 14, 202210-Q10-QNov 9, 202210-Q10-QAug 12, 20228-KShareholder VoteJun 9, 2022S-1S-1May 27, 202210-Q10-QMay 13, 2022DEFA14ADEFA14AApr 25, 2022DEF 14ADEF 14AApr 25, 202210-K10-KMar 28, 2022SC 13GSC 13GFeb 9, 20228-KCompany UpdateJan 19, 20228-KCompany UpdateJan 12, 20228-KCompany UpdateJan 3, 2022SC 13GSCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIPDec 28, 20218-KBylaw Amendment · Company UpdateDec 20, 2021424B4424B4Dec 17, 2021S-1/AS-1/ANov 4, 2021S-1/AS-1/AOct 28, 2021S-1/AS-1/AOct 15, 2021
Insider Activity
◆ Cluster Buy · 2 insidersIn the 90 days to Dec 10, 2025: 2 insiders bought $10K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 10, 2025 | Morris Gabriel SCFO | Buy | 770 | $6.58 | $5K |
| Dec 10, 2025 | Rachman Ilya MCEO and Chairman | Buy | 746 | $6.67 | $5K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance